Why the study?
Does long-term sibutramine treatment affect cardiovascular outcomes in overweight and obese subjects with preexisting cardiovascular conditions?
Does long-term sibutramine treatment affect cardiovascular outcomes in overweight and obese subjects with preexisting cardiovascular conditions?
Long-term sibutramine treatment in overweight and obese patients with preexisting cardiovascular conditions increases the risk of nonfatal myocardial infarction and stroke.
Answers are grounded in this paper and cite their sources.
Avoid sibutramine in overweight patients with cardiovascular disease; confirms harm on nonfatal events in this RCT.
Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
No takes yet. Share an insight, caveat, or question.
James et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: